Combined therapy of metformin and moderate FODMAP diet significantly reduces postprandial glucose excursions and enhances GLP-1 secretion in prediabetic patients.
Moderate FODMAP intake increases abundance of beneficial butyrate-producing bacteria and reduces systemic inflammation markers.
No significant increase in gastrointestinal side effects observed compared to low FODMAP intake during metformin therapy.
Baseline abundance of Dorea formicigenerans may predict metformin intolerance, highlighting gut microbiota’s role in drug response.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
